A Universal Influenza A and B Duplex Real-time RT-PCR Assay

Hong Kai Lee,1,2 Tze Ping Loh,3 Chun Kiat Lee,1 Julian Wei-Tze Tang,4,5 Lily Chiu,1 and Evelyn Siew-Chuan Koay1,2*

1Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore
2Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3Clinical Chemistry, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore
4Alberta Provincial Laboratory for Public Health, University of Alberta Hospital, Edmonton, Canada
5Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada

A high throughput universal influenza A and B duplex real-time RT-PCR was developed to meet effectively the heightened surveillance and diagnostic needs essential in managing influenza infections and outbreaks. Primers and probes, designed to target highly conserved regions of the matrix protein of influenza A and the nucleoprotein of influenza B, were optimized using the high-throughput LightCycler 480 II system. Analytical sensitivity and specificity were characterized using RNA transcripts diluted serially, archived non-influenza respiratory viruses, and proficiency test samples. Eighty-nine clinical samples were tested in parallel against existing influenza A and B monoplex assays. Once validated, the duplex assay was applied prospectively on 2,458 clinical specimens that were later subtyped. In April 2011, the emergence of an influenza B variant necessitated the inclusion of an additional modified probe for influenza B and revalidation of the revised protocol. The lower detection limits of the assay were 50 copies/PCR. There was no cross-reactivity against any non-influenza respiratory virus and all proficiency testing materials were identified correctly. The parallel testing revealed a 98.9% overall agreement. Routine application of the assay revealed high sensitivity and specificity for the detection of influenza A/H1N1/2009, A/H3N2 and influenza B. Assay C_q values correlated well between the pre- and post-revision protocols for influenza A \( (r^2 = 0.998) \) and B \( (r^2 = 0.999) \). The revised protocol detected three additional novel influenza B variant cases in 200 specimens reported previously as influenza B negative. This in-house assay offers a highly sensitive and specific option for laboratories seeking to expand their influenza testing capacity. J. Med. Virol. 84:1646–1651, 2012. © 2012 Wiley Periodicals, Inc.

KEY WORDS: influenza; PCR; influenza A; influenza B; surveillance; H1N1/2009

INTRODUCTION

In April 2009, a novel swine-origin influenza A (family Orthomyxoviridae, genus Influenzavirus A) emerging from Mexico was detected in the United States of America [Dawood et al., 2009]. By the end of May 2009, it had spread to over 40 countries worldwide [WHO, 2009a]. While the classification of this novel influenza virus as a pandemic strain has been debated [Cohen and Carter, 2010; Evans, 2010; Tang et al., 2010], it has prompted a reassessment of recent pandemic preparedness practices [Cordova-Villalobos et al., 2009; Del Rio and Hernandez-Avila, 2009; del Rio and Guarner, 2010; Rizzo et al., 2010; Tay et al., 2010]. An important lesson identified in many retrospective studies was the importance of collecting, analyzing and disseminating high quality surveillance

© 2012 WILEY PERIODICALS, INC.
data for informing diagnostic, therapeutic and public health interventions [Cordova-Villalobos et al., 2009; Kumar et al., 2010; Rizzo et al., 2010; Sigmundsdottir et al., 2010; Tay et al., 2010].

Molecular testing is an essential surveillance tool, particularly when existing conventional viral culture and immunoﬂuorescence testing is inadequate for detecting emerging, novel viruses [Lee et al., 2010; Tay et al., 2010]. Several real-time reverse transcription PCR (rRT-PCR) assays that have been developed for simultaneous detection of influenza A and B viruses in single-tube format, may ﬁt this purpose [Selvaraman et al., 2010; Chen et al., 2011; Huber et al., 2011; Papillard-Marechal et al., 2011; Shisong et al., 2011; Li et al., 2012; Salez et al., 2012]. However, the robustness of these assays has not been characterized extensively on routine clinical samples or proﬁciency testing materials. A sensitive and speciﬁc high-throughput duplex universal inﬂuenza A and B rRT-PCR method is described, which was validated on 2,458 clinical specimens and proﬁciency testing material from the Quality Control for Molecular Diagnostics and the Royal College of Pathologists of Australasia external quality assurance programs.

MATERIALS AND METHODS

Specimen Preparation

This study was approved by the local institutional ethics review board (National Healthcare Group Domain-Speciﬁc Review Board, reference numbers: B/09/360 and E/09/341). The protocol for respiratory sample collection and processing at the National University Hospital, Singapore had been described previously in detail [Lee et al., 2010]. The demographic details of the patients are summarized in Table I. Briefly, nasopharyngeal/nasal swabs collected into 3 ml of universal transport medium (Copan Diagnostics, Corona, CA) or dry/gel swabs pretreated with 1×-phosphate buffered saline (PBS), were kept at 4°C and processed within 24 hr. Viral RNA was extracted from 200 μl of the universal transport solution, or 200 μl of the 1×-PBS or from 200 μl of 1% N-acetylcycteine in 1×-PBS used to pre-treat sputum/endotracheal aspirates. The extracted viral RNA was eluted in 60 μl of the eluent.

| Demography          | Frequency (%) |
|---------------------|--------------|
| Gender              |              |
| Male                | 1,391 (54.6%)|
| Female              | 1,156 (45.4%)|
| Age group           |              |
| Paediatric (<18-year-old) | 901 (35.4%) |
| Adult               | 1,538 (60.4%)|
| Unknown             | 8 (0.3%)     |
| Ordering location   |              |
| Inpatient           | 1,092 (43.9%)|
| Outpatient          | 1,297 (50.9%)|
| Outreach            | 158 (6.2%)   |

Extraction was carried out on either the Bio Robot EZ1 or the QIAsymphony automated platforms (Qiagen, Valencia, CA), using the Qiagen EZ1 Virus mini kit v2.0 or the QIAsymphony Virus/Bacteria mini kit, respectively, according to the manufacturer’s instructions.

Real-Time Reverse Transcription Polymerase Chain Reaction

The amplification and detection of inﬂuenza A and B viral RNA were performed in a single tube using the 5′ exonuclease probe rRT-PCR method. To ensure the detection of all inﬂuenza A and B subtypes, primers and probes with minimum secondary structures were designed, targeting the highly conserved regions of the matrix protein (A/California/07/2009(H1N1), GenBank accession: FJ969537) and nucleoprotein (B/North Carolina/WRAIR1582P/2009, GenBank accession: CY069566) genes, respectively.

The rRT-PCR was performed on the LightCycler 480 II System (Roche Molecular Diagnostics, Pleasanton, CA), using the SuperScript III Platinum One-step qRT-PCR reagent kit (Invitrogen, Carlsbad, CA). The 20-μl reaction volume is comprised of 5 μl of extracted RNA template, 0.5 μl of enzyme mix, 10 μl of 2× reaction mix, 0.25 μmol/L inﬂuenza A forward primer, 0.2 μmol/L inﬂuenza A reverse primer, 0.25 μmol/L inﬂuenza A probe, 0.25 μmol/L inﬂuenza B forward primer, 0.2 μmol/L inﬂuenza B reverse primer, and 0.25 μmol/L inﬂuenza B original probe. All primers and probes were purchased from Eurogentec AIT (Seraing, Belgium) and listed in Table II.

The rRT-PCR was initiated by reverse transcription (55°C, 8 min) and initial denaturation (95°C, 2 min), followed by 45 ampliﬁcation cycles at 95°C for 15 sec, 60°C for 20 sec, and 68°C for 15 sec. Fluorescence signals were collected at every 68°C stage. The inﬂuenza A and B ampliﬁcation signal curves were analyzed at absorption wavelengths of 530 nm (FAM) and 560 nm (Yellow Yakima), respectively. Both ﬂuorescence signals were color-compensated according to the manufacturer’s recommendation. Appropriate positive control and non-template control were included in every test run.

Analytical Specificity

The speciﬁcity of the assay was evaluated using archived patient samples that were previously tested positive for human metapneumovirus, respiratory syncytial virus, para-inﬂuenza virus types 1–4, and coronaviruses (229E and OC43). Proficiency testing materials for the inﬂuenza A and B panels, provided by the Quality Control for Molecular Diagnostics and the Royal College of Pathologists of Australasia, were also used to assess the assay performance. Additionally, in silico analysis was performed to further characterize the speciﬁcity of the inﬂuenza A primers and probe by aligning the oligonucleotides against inﬂuenza A sequences published within the most

J. Med. Virol. DOI 10.1002/jmv
recent 5 years in GenBank (n = 200) that included H1N1/2009, seasonal H1N1, seasonal H3N2, and H5N1 subtypes.

In addition, in order to assess the capability of this assay to detect the recent novel reassortant influenza A/H3N2v, all the sequences available for this virus [Lindstrom et al., 2012] were downloaded for an in silico comparison, that is, JN638729, JQ070795, JN655534, JQ070780, and JQ290167.

### Clinical Sensitivity and Specificity

The agreement between the universal influenza A/B duplex assay and the existing modified influenza A and influenza B monoplex assays [Lee et al., 2010] was determined by parallel testing of 89 consecutive clinical samples received for routine testing between March 31 and April 10, 2010. The 89 samples were further subjected to H1N1/2009 and seasonal H1N1/H3N2 subtyping assays for identification [Lee et al., 2010]. Upon completion of the initial evaluation, the duplex assay was implemented as the influenza-screening assay at the National University Hospital, Singapore. Specimens testing positive for influenza A using the duplex assay were further subtyped with an in-house developed H1N1/2009 dual-gene rRT-PCR [Lee et al., 2010] and published seasonal H1N1 and H3N2 subtyping assays [HKCHP, 2009].

### Discovery of Influenza B Variant Strain and Addition of Influenza B Probe

On April 12, 2011, after the routine application of this laboratory-developed assay, a novel influenza B variant (B/Singapore/1/2011, GenBank accession: CY093580) that was detected by direct immunofluorescence staining and virus culture, tested negative on this assay. The cause of failure to detect the variant virus by this assay was the presence of two single nucleotide substitutions at the probe region of the assay. This incidence has been described in detail [Lee et al., 2011b]. To overcome this, an additional probe that fully complements the influenza B variant was designed (Table II), and included in equimolar amounts with the original probe to a final concentration of 0.25 μmol/L. The revised protocol was tested in parallel with the original method that contained only the original probe, on each of 20 randomly selected influenza A/H1N1/2009, A/H3N2, and B positive samples with Cq values between 15.8 and 37.3. Furthermore, 200 clinical specimens that had been reported as negative for influenza A/B during April 2011 using the original method was retested with this revised protocol. Any positive sample arising from this additional testing was subjected to Sanger sequencing to confirm the identity of the pathogen.

### Lower Detection Limit of Revised Protocol

The amplicons of the matrix protein of influenza A and the nucleoprotein of influenza B were cloned into the pCR2.1-TOPO cloning vector (Invitrogen) and transcribed in vitro into RNA transcripts using RibomAX Large Scale RNA Production System-T7 (Promega, Madison, WI), according to manufacturers’ instructions. The sequences of the cloned plasmids were confirmed by direct sequencing prior to transcription. The synthesized transcripts were quantified using the NanoDrop ND-1000 UV–Vis spectrophotometer (Thermo Fisher Scientific, Wilmington, DE), using absorption wavelength of 260 nm. The lower detection limit and linearity studies of the revised universal influenza A and B rRT-PCR assay were performed in triplicates, using transcripts diluted serially in 10-fold (1 × 10^8 copies/μL).

### RESULTS

#### Analytical Specificity

The duplex assay did not exhibit any cross-reactivity towards any non-influenza respiratory viruses in the archived specimens. The universal influenza A/B assay was also able to identify correctly all the proficiency testing materials provided by the Quality Control for Molecular Diagnostics and Royal College of Pathologists of Australasia.

In silico analysis of the sequences of the universal influenza A primers and probes against the A/H1N1/
2009, seasonal A/H3N2, and A/H3N2/v virus sequences showed 100% complementation. Single base-pair mismatches were found near the 5’ end of the forward primer against seasonal H1N1, and the 5’ ends of the forward and reverse primers against the H5N1 strain, but these were not expected to affect significantly the performance of the assay.

**Clinical Sensitivity and Specificity**

Of the 89 clinical specimens tested in parallel, 26 were positive for influenza A using the duplex assay, one more than the 25 detected by the existing monoplex influenza A assay. All influenza A positive cases were confirmed by the H1N1/2009 and seasonal H1N1/H3N2 subtyping assays. There were 25 H1N1/2009 and 1 H3N2 positives detected. The discrepant specimen was identified as H1N1/2009 by the subtyping assay. The overall percent agreement was 98.9% (96.1% positive agreement; 100% negative agreement).

For influenza B detection, the duplex screening assay detected an additional influenza B positive case \((n = 3)\) compared to the two positives detected by the existing monoplex influenza B method.

Between April 10, 2010 and January 5, 2011, the universal influenza A/B duplex assay was tested on 2,458 samples. During this period, there were 640 influenza A, 146 influenza B, and 2 influenza A/H1N1/2009 and B co-infections detected. Of the 640 influenza A positive cases, 355 were confirmed as H1N1/2009, 270 as seasonal H3N2, and 2 as seasonal H1N1 subtypes (98.0% positive agreement). The 13 cases that were not detected by the subtyping methods had \(C_q\) values between 36.2 and 40 on the duplex assay.

Although this assay should, from the in silico analysis, be able to detect the A/H3N2/v reassortant virus, unfortunately, no positive sample was available for experimental testing, so the potential for this assay to detect this strain remains undetermined.

**Comparison Between Pre- and Post-revision Protocols**

Comparison between the pre- and post-revision universal influenza A/B protocols showed good correlation of the \(C_q\) values, with \(r^2 = 0.998\) and 0.999 for influenza A and B detection, respectively (Fig. 1A and B). Of the 200 previously influenza negative samples tested by the revised protocol, 3 additional influenza B/Singapore/1/2011 samples were identified and confirmed by Sanger sequencing [Lee et al., 2011b].

**Lower Limit of Detection**

The estimated lower limits of detection of the revised universal influenza A/B duplex assay were similar for influenza A/H1N1, A/H3N2, and B at 50 copies/PCR. A summary of the \(C_q\) values at concentrations of 5–5 \(\times\) 10\(^8\) copies/PCR is provided in Table III. The

**DISCUSSION**

The use of universal influenza assays are important to identify influenza patients, not just for seasonal but now for pandemic A/H1N1 and avian A/H5N1 influenza viruses, which are now known to be less detected readily by more traditional diagnostic virology methods, such as cell culture and immunofluorescence assays [WHO, 2005a, 2009b]. The targeting of highly conserved regions of the continually evolving influenza virus more reliably ensures the detection of all strains, including novel strains. Subsequent failure to subtype a patient into H1N1/2009, seasonal H3N2 or H1N1 should raise the suspicion of a novel variant or, more rarely, a novel subtype, or perhaps an avian A/H5N1 infection [WHO, 2005a, 2009b].

This universal influenza A/B assay was able to achieve better specificity and sensitivity compared to the existing monoplex assays. In addition, optimizing this assay for a high-throughput platform, the
LightCycler® 480 II, may make it more applicable for diagnostic laboratories with high workloads. The 13 discrepant cases that were undetected by the subtyping assays were likely due to stochastic variations at low viral loads approaching the lower limit of detection of the assays. The quantitative capability of this universal influenza A assay has been demonstrated in a viral load comparison study between influenza A/H1N1/2009, seasonal influenza A/H1N1, and A/H3N2 in Singapore [Lee et al., 2011a].

Within the month of April 2011, four out of five influenza B positive samples detected during routine diagnostic testing turned out to be a new variant, later named as influenza B/Singapore/1/2011. This potential drift variant was missed by the primers and probes of the earlier version of this influenza A/B duplex screening assay and a redesign was undertaken [Lee et al., 2011b]. The good correlation between the Cq values of the pre- and post-revision protocols [Lee et al., 2011b]. The good correlation between the Cq values of the pre- and post-revision protocols demonstrated that the performance of the redesigned assay had not been affected adversely by the inclusion of the additional probe.

In conclusion, this duplex universal influenza A/B assay offers a useful option for laboratories requiring a high-throughput testing capacity, with the simultaneous detection of influenza A and B viruses saving time and cost. This may be particularly useful in the post-pandemic influenza era when heightened awareness and continued surveillance by hospital clinical teams and community general practitioners may increase the diagnostic laboratory workload. This assay also fulfils the ongoing surveillance needs in all phases of pandemic preparedness planning, as recommended by the World Health Organization [WHO, 2005b], and in addition, has demonstrated the potential, at least in silico, to detect the recent reassortant virus, A/H3N2/v.

Cohen D, Carter P. 2010. Conflicts of interest, WHO and the pandemic flu "conspiracies." Brit Med J 340:c2912.

Cordova-Villalobos JA, Sarti E, Arroz-Padres J, Manuel-Lee G, Mendez JR, Kuri-Morales P. 2009. The influenza A(H1N1) epidemic in Mexico. Lessons learned. Health Res Policy Syst 7:21.

Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bingham CB, Uyeki TM. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:2605–2615.

del Rio C, Guarner J. 2010. The 2009 influenza A (H1N1) pandemic: What have we learned in the past 6 months. Trans Am Clin Climatol Assoc 121:128–137; discussion 138–140.

Del Rio C, Hernandez-Avila M. 2009. Lessons from previous influenza pandemics and from the Mexican response to the current influenza pandemic. Arch Med Res 40:677–680.

Evans MR. 2010. The swine flu scam? J Public Health (Oxf) 32:296–297.

Hong Kong Centre for Health Protection (HKCHP). 2009. CHMP molecular diagnostic protocols for the detection of human swine influenza virus type A (subtype H1). Available at: http://www.chmp.gov.hk/files/pdf/CHMP_Protocols_for_the_Detection_of_Human_Swine_Influenza.pdf (Last accessed on November 16, 2011).

Huber I, Campe H, Sebah D, Hartberger C, Konrad R, Bayer M, Busch U, Sing A. 2011. A multiplex one-step real-time RT-PCR assay for influenza surveillance. Euro Surveill 16 pii:19708.

Kumar S, Chusid MJ, Willougby RE, Havens PL, Kehl SC, Leboer NA, Simpson P, Vandyke M, Davis E, Gaffney K, Li SH, Bose ME, Henrickson KJ. 2010. Epidemiologic observations from passive and targeted surveillance during the first wave of the 2010/2011 H1N1 influenza pandemic in Milwaukee, WI. Viruses 2:782–795.

Lee HK, Lee CK, Loh TP, Tang JW. 2011a. Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, Singapore. Emerg Infect Dis 17:287–291.

Lee HK, Lee CK, Loh TP, Tang JW. 2011b. Missed diagnosis of influenza B virus due to nucleoprotein sequence mutations, Singapore, April 2011. Euro Surveill 16 pii:19943.

Li M, Brenwald N, Bonigal S, Chana K, Osman H, Oppenheim B, Barnes N, Sleeman K, Gubareva L, Villanueva J, Klimov A. 2012. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 18:834–837.

Lindstrom S, Garten R, Balish A, Shu B, Emery S, Berman L, Barnes N, Sleeman K, Gubareva L, Villanueva J, Klimov A. 2012. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 18:834–837.

Papillard-Marechal S, Enouf V, Schnarnger A, Vabret A, Macheras E, Rameix-Welti MA, Page B, Freymuth F, van der Werf S, Garbarz-Chenon A, Chevallier B, Guillard JL, Gault E. 2011. Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus. J Med Virol 83:695–701.

REFERENCES

Chen Y, Cui D, Zheng S, Yang S, Tong J, Yang D, Fan J, Zhang J, Lou B, Li X, Zhuo X, Ye B, Chen B, Mao W, Tan Y, Xu G, Chen Z, Chen N, Li L. 2011. Simultaneous detection of influenza A, influenza B, and respiratory syncytial viruses and subtyping of influenza A H3N2 virus and H1N1 (2009) virus by multiplex real-time PCR. J Clin Microbiol 49:1653–1656.

J. Med. Virol. DOI 10.1002/jmv

| Log (copies/PCR) | H3N2 | H1N1/2009 | Flu B |
|-----------------|------|----------|-------|
| Mean | SD  | Mean | SD  | Mean | SD  |
| 0.7  | 40.00 | —     | 40.00 | —     | —     |
| 1.7  | 37.92 | 1.44   | 37.52 | 0.59  | 38.89 | 0.97 |
| 2.7  | 35.39 | 0.35   | 34.37 | 0.30  | 35.53 | 0.29 |
| 3.7  | 31.79 | 0.08   | 30.64 | 0.10  | 32.13 | 0.10 |
| 4.7  | 28.44 | 0.09   | 27.34 | 0.10  | 28.65 | 0.06 |
| 5.7  | 24.94 | 0.02   | 23.85 | 0.04  | 25.20 | 0.03 |
| 6.7  | 21.53 | 0.06   | 20.40 | 0.10  | 21.76 | 0.10 |
| 7.7  | 18.00 | 0.08   | 16.91 | 0.02  | 18.23 | 0.06 |
| 8.7  | 14.64 | 0.06   | 13.57 | 0.04  | 14.91 | 0.07 |

| Log (copies/PCR) | Mean | SD  |
|-----------------|------|-----|
| 0.7  | 40.00 | —   |
| 1.7  | 37.92 | 1.44 |
| 2.7  | 35.39 | 0.35 |
| 3.7  | 31.79 | 0.08 |
| 4.7  | 28.44 | 0.09 |
| 5.7  | 24.94 | 0.02 |
| 6.7  | 21.53 | 0.06 |
| 7.7  | 18.00 | 0.08 |
| 8.7  | 14.64 | 0.06 |
Rizzo C, Rota MC, Bella A, Giannitelli S, De Santis S, Nacca G, Pompa MG, Vellucci L, Salmaso S, Declich S. 2010. Response to the 2009 influenza A(H1N1) pandemic in Italy. Euro Surveill 15:pii:19744.

Salez N, Ninove L, Thirion L, Gazin C, Zandotti C, de Lamballerie X, Charrel RN. 2012. Evaluation of the Xpert Flu test and comparison with in-house real-time RT-PCR assays for detection of influenza virus from 2008 to 2011 in Marseille, France. Clin Microbiol Infect 18:E81–E83.

Selvaraju SB, Selvarangan R. 2010. Evaluation of three influenza A and B real-time reverse transcription-PCR assays and a new 2009 H1N1 assay for detection of influenza viruses. J Clin Microbiol 48:3870–3875.

Shisong F, Jianxiong L, Xiaowen C, Cunyou Z, Ting W, Xing L, Xin W, Chunli W, Ronli Z, Jinquan C, Hong X, Muhua Y. 2011. Simultaneous detection of influenza virus type B and influenza A virus subtypes H1N1, H3N2, and H5N1 using multiplex real-time RT-PCR. Appl Microbiol Biotechnol 90:1463–1470.

Sigmundsdottir G, Gudnason T, Olafsson O, Baldvinsdottir GE, Atladottir A, Love A, Danon L, Briem H. 2010. Surveillance of influenza in Iceland during the 2009 pandemic. Euro Surveill 15:pii:19742.

Tang JWT, Loh TP, Koay ESC. 2010. Influenza A/H1N1/2009: A pandemic or not a pandemic—A perspective from the tropics. Brit Med J Rapid Response 340:c2912.

Tay J, Ng YF, Cutter JL, James L. 2010. Influenza A (H1N1-2009) pandemic in Singapore—public health control measures implemented and lessons learnt. Ann Acad Med Singapore 39:313–12.

WHO. 2005a. Recommended laboratory tests to identify avian influenza A virus in specimens from humans. Geneva: WHO. Available at: www.cdc.gov.tw/downloadfile.aspx?fid=FCE2E4E34EB2CCE3 (Last accessed on November 16, 2011).

WHO. 2005b. WHO checklist for influenza pandemic preparedness planning. Epidemic Alert & Response. Available at: http://www.who.int/influenza/resources/documents/FluCheck6web.pdf (Last accessed on November 16, 2011).

WHO. 2009a. Influenza A(H1N1)—Update 41. Global Alert and Response (GAR). Available at: http://www.who.int/csr/don/2009_05_29/en/ (Last accessed on November 16, 2011).

WHO. 2009b. WHO information for laboratory diagnosis of pandemic (H1N1) 2009 virus in humans—Revised. Geneva: WHO. Available at: http://www.who.int/csr/resources/publications/swineflu/WHO_Diagnostic_RecommendationsH1N1_20090521.pdf (Last accessed on November 16, 2011).